Abstract
Rare missense variants are often classified as variants of uncertain significance (VUS) due to insufficient evidence for classification. These ambiguous findings create anxiety and frequently lead to inappropriate workup, colloquially referred to as the ‘diagnostic odyssey’. Well-validated high-throughput experimental data have the potential to significantly reduce the number of VUS identified by clinical genetic testing, though the extent of this reduction and the optimal strategies to achieve it remain unclear.1
Competing Interest Statement
SRP, YT, FF, MV, SRP, and JR are current or former employees of Labcorp (formerly Invitae Corporation).
Funding Statement
This research was funded by the National Institutes of Health: R01HL164675 and R01HL160863 (BMK); the Leducq Transatlantic Network of Excellence Program 18CVD05 (BMK); a New South Wales Cardiovascular Disease Senior Scientist grant (JIV); and a Medical Research Future Fund: Genomics Health Futures Mission grant MRF2016760 (CAN/JIV). We also acknowledge support from the Victor Chang Cardiac Research Institute Innovation Centre, funded by the New South Wales Government, Australia.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data were deidentified and approved for use in this study by WCG Institutional Review Board (study number 1167406).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.